Infectious Disease Special Edition news story
Switching to long-acting injectable cabotegravir-rilpivirine (CAB/RPV; Cabenuva, ViiV Healthcare) every two months maintained virologic suppression as effectively as switching to daily oral bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF; Biktarvy, Gilead) in a large real-world U.S. cohort, according to findings presented at AIDS 2026.
The analysis used electronic health record data from the OPERA cohort, which included 101 clinics and represented approximately 14% of people living with HIV in the United States. Investigators evaluated treatment-experienced adults who were virologically suppressed before switching for the first time to either regimen between February 2022 and March 2025.
Read the full news story here.
/free registration is required/
View all Infectious Disease Special Edition reports from AIDS 2026
Source : Infectious Disease Special Edition
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.